Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine

The tumor-associated antigen mucin 1 (MUC1) is an attractive target of antitumor vaccine, but its weak immunogenicity is a big challenge for the development of vaccine. In order to enhance immune responses against MUC1, herein, we conjugated small molecular toll-like receptor 7 agonist (TLR7a) to ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shi-Hao, Li, Yu-Ting, Zhang, Ru-Yan, Liu, Yan-Ling, You, Zi-Wei, Bian, Miao-Miao, Wen, Yu, Wang, Jian, Du, Jing-Jing, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965739/
https://www.ncbi.nlm.nih.gov/pubmed/35371101
http://dx.doi.org/10.3389/fimmu.2022.857779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965739/
https://www.ncbi.nlm.nih.gov/pubmed/35371101
http://dx.doi.org/10.3389/fimmu.2022.857779

Ejemplares similares